加载中
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
收盘时
US$24.15
−US$0.59 · -2.38%
盘后
US$24.15
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日内区间
当前US$24.15
52周区间
当前US$24.15
盘中时间采用ET。市场数据可能有所延迟。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日内区间
当前US$24.15
52周区间
当前US$24.15
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.84亿 USD | 3655.5万 USD | 878万 USD | 1240.5万 USD | — |
| 毛利 | 1.84亿 USD | 3655.5万 USD | 878万 USD | 1240.5万 USD | — |
| 研究与开发 | 1.38亿 USD | 8913.3万 USD | 8223.1万 USD | 7783.7万 USD | 5416.8万 USD |
| 销售、一般及管理费用 | 6708.8万 USD | 4879.4万 USD | 4132.2万 USD | 3892.4万 USD | 3189.7万 USD |
| 营业费用 | 2.05亿 USD | 1.38亿 USD | 1.24亿 USD | 1.17亿 USD | 8606.5万 USD |
| 利息收入 | 1376.5万 USD | 1263.8万 USD | 990.8万 USD | 312.2万 USD | 12万 USD |
| 利息支出 | 9000 USD | — | — | — | — |
| 折旧和摊销 | 177万 USD | 217.7万 USD | 246.9万 USD | 154.6万 USD | 97.4万 USD |
| 营业利润 | −2059万 USD | −1.01亿 USD | −1.15亿 USD | −1.04亿 USD | −8606.5万 USD |
| 净利润 | −688.5万 USD | −8898.1万 USD | −1.05亿 USD | −1.01亿 USD | −8580.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5901.32万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM3559.17万0.05%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI3194.79万0.32%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF2029.21万0.02%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1259.25万0.09%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1027.84万0.09%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO987.82万0.05%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS867.44万0.03%338.69亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
